Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Evestia Clinical and Atlantic Research Group Join Forces to Create Global CRO Powerhouse

Evestia Clinical and Atlantic Research Group Join Forces to Create Global CRO Powerhouse

In a significant move that reshapes the landscape of contract research organizations (CROs), Evestia Clinical and Atlantic Research Group have announced their merger to form a global entity. The newly combined company, which will retain the Evestia Clinical name, aims to leverage the strengths of both organizations to provide enhanced expertise in key therapeutic areas and late-stage clinical trials.

NoahAI News7/16/2025
CalPERS Announces New PBM Contract with CVS Caremark, Emphasizing Risk-Based Performance

CalPERS Announces New PBM Contract with CVS Caremark, Emphasizing Risk-Based Performance

The California Public Employees' Retirement System (CalPERS) has unveiled a groundbreaking pharmacy benefit manager (PBM) contract with CVS Caremark, set to take effect in 2026. This strategic move, announced on Tuesday, marks a significant shift in CalPERS' approach to managing prescription drug benefits for nearly 600,000 of its members.

NoahAI News7/16/2025
GSK Reshapes R&D Strategy with Job Cuts and Major Investments

GSK Reshapes R&D Strategy with Job Cuts and Major Investments

GSK, the British pharmaceutical giant, is embarking on a significant restructuring of its research and development (R&D) operations, balancing job cuts with substantial investments to fuel its ambitious growth strategy. The company aims to bring 14 new medicines with blockbuster sales potential to market before 2031, a goal that has driven a nearly 90% increase in R&D investment since 2018.

NoahAI News7/16/2025
HHS Implements Controversial Workforce Reduction Amid Legal Challenges

HHS Implements Controversial Workforce Reduction Amid Legal Challenges

The Department of Health and Human Services (HHS) has begun implementing a contentious reduction in force (RIF) following a Supreme Court decision that lifted a lower court's block on the layoffs. This move marks a significant development in the ongoing restructuring of the agency under Secretary Robert F. Kennedy, Jr.'s leadership.

NoahAI News7/16/2025
GSK Expands Agreement with Medicines Patent Pool for Generic Production of Cabotegravir

GSK Expands Agreement with Medicines Patent Pool for Generic Production of Cabotegravir

GSK has broadened its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, a move that will allow three generic drugmakers to produce and supply the HIV treatment to patients in low- and middle-income countries. This expansion comes on the heels of updated guidance from the World Health Organization (WHO) recommending long-acting injectable treatments as an alternative to daily oral therapy for virally suppressed patients.

NoahAI News7/16/2025
Hengrui's Dual GLP-1/GIP Agonist Shows Promising Results in Phase III Obesity Trial

Hengrui's Dual GLP-1/GIP Agonist Shows Promising Results in Phase III Obesity Trial

Hengrui Pharma, in collaboration with Massachusetts-based Kailera Therapeutics, has announced impressive topline results from a Phase III trial of their dual GLP-1/GIP receptor agonist, HRS9531, for the treatment of obesity. The study, conducted in Shanghai, China, demonstrated significant weight loss in patients, positioning the drug as a potential breakthrough in obesity management.

NoahAI News7/15/2025
Hengrui and Kailera's Dual-Acting Obesity Drug Shows Promise in Phase 3 Trial

Hengrui and Kailera's Dual-Acting Obesity Drug Shows Promise in Phase 3 Trial

Hengrui Pharma and Kailera Therapeutics have announced positive results from a Phase 3 trial of their experimental dual-acting obesity drug, HRS9531, conducted in China. The once-weekly injection demonstrated significant weight loss efficacy, positioning the companies to seek approval in China and initiate global late-stage testing.

NoahAI News7/15/2025
Pharmaceutical Industry Roundup: Vertex's Cystic Fibrosis Drug Approved, Merck Advances HIV Prevention, and Atara Resubmits Cell Therapy Application

Pharmaceutical Industry Roundup: Vertex's Cystic Fibrosis Drug Approved, Merck Advances HIV Prevention, and Atara Resubmits Cell Therapy Application

In a series of significant developments across the pharmaceutical landscape, several major players have made strides in drug approvals, clinical trials, and regulatory submissions. From expanded access to cystic fibrosis treatments to advancements in HIV prevention, the industry continues to push forward in addressing critical healthcare needs.

NoahAI News7/15/2025
Sino Biopharm Acquires LaNova Medicines in $951M Deal, Bolstering Oncology Pipeline

Sino Biopharm Acquires LaNova Medicines in $951M Deal, Bolstering Oncology Pipeline

Sino Biopharmaceutical, a leading Chinese pharmaceutical company, has announced its acquisition of LaNova Medicines for up to $951 million, marking a significant development in the oncology drug development landscape. The deal, which involves Sino Biopharm purchasing the remaining 95.09% stake in LaNova, comes on the heels of several high-profile partnerships between Chinese biotechs and Western pharmaceutical giants.

NoahAI News7/15/2025
GSK's Blenrep Faces FDA Scrutiny Over Eye Safety Concerns Ahead of Potential U.S. Return

GSK's Blenrep Faces FDA Scrutiny Over Eye Safety Concerns Ahead of Potential U.S. Return

GSK's antibody-drug conjugate (ADC) Blenrep is under close examination by the U.S. Food and Drug Administration (FDA) as the company seeks to reintroduce the multiple myeloma treatment to the American market. The FDA has raised significant concerns about ocular toxicity and dosage optimization ahead of a crucial advisory committee meeting.

NoahAI News7/15/2025
Acumen and JCR Pharmaceuticals Forge $555M Alliance to Tackle Alzheimer's Disease

Acumen and JCR Pharmaceuticals Forge $555M Alliance to Tackle Alzheimer's Disease

Acumen Pharmaceuticals and JCR Pharmaceuticals have announced a groundbreaking collaboration worth up to $555 million, aimed at developing novel therapies for Alzheimer's disease. This partnership combines Acumen's expertise in amyloid beta oligomer (AβO)-selective antibodies with JCR's innovative blood-brain barrier penetration technology, potentially revolutionizing the treatment landscape for neurodegenerative disorders.

NoahAI News7/15/2025
M7 Health Secures $10M to Revolutionize Nurse Staffing and Scheduling

M7 Health Secures $10M to Revolutionize Nurse Staffing and Scheduling

In a significant development for the healthcare workforce management sector, M7 Health has successfully raised $10 million in Series A funding to expand its innovative nurse staffing and scheduling platform. The investment, led by Threshold Ventures with participation from First Round Capital, 25m Health, and Lakehouse, brings M7 Health's total funding to $17 million to date.

NoahAI News7/15/2025
«1...161718...67»